Darrah Justin M, Herrera Alex F
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Department of Hematology and Oncology, Harbor-UCLA Medical Center, Torrance, CA, USA.
Curr Hematol Malig Rep. 2018 Oct;13(5):348-355. doi: 10.1007/s11899-018-0468-4.
The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications.
Recent studies have demonstrated the use of ctDNA assessment across many lymphoma subtypes including diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin lymphoma, and T-cell lymphoma. In addition, many novel applications of ctDNA assessment have been described such as the development of new prognostic models, investigation of clonal evolution and heterogeneity, early assessment of treatment response, and prediction of response to targeted therapy as a form of personalized medicine. The use of ctDNA has been shown to be feasible across many lymphoma subtypes and has shown significant promise for several new applications. Additional studies will be needed to validate these findings prior to routine use in clinical practice.
循环肿瘤DNA（ctDNA）用于淋巴瘤的诊断、预后评估、治疗反应评估及复发监测是一个新兴且不断发展的领域。本综述旨在总结ctDNA应用方面的许多最新进展。
近期研究已证实ctDNA评估可用于多种淋巴瘤亚型，包括弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤、霍奇金淋巴瘤和T细胞淋巴瘤。此外，还描述了ctDNA评估的许多新应用，如开发新的预后模型、研究克隆进化和异质性、早期评估治疗反应以及预测靶向治疗反应作为个性化医疗的一种形式。已证明ctDNA在多种淋巴瘤亚型中的应用是可行的，并且在一些新应用方面显示出巨大潜力。在临床实践中常规使用之前，还需要更多研究来验证这些发现。
